BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 26044925)

  • 21. The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis.
    Song JH; Wu HG; Keam BS; Hah JH; Ahn YC; Oh D; Noh JM; Park HJ; Lee CG; Keum KC; Cha J; Cho KH; Moon SH; Kim JY; Chung WK; Oh YT; Kim WT; Cho MJ; Kay CS; Kim YS
    Cancer Res Treat; 2016 Jul; 48(3):917-27. PubMed ID: 26727716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Addition of Definitive Radiotherapy to Chemotherapy in Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer.
    Verma V; Allen PK; Simone CB; Gay HA; Lin SH
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1383-1391. PubMed ID: 29118230
    [No Abstract]   [Full Text] [Related]  

  • 23. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial.
    Ke LR; Xia WX; Qiu WZ; Huang XJ; Yang J; Yu YH; Liang H; Liu GY; Ye YF; Xiang YQ; Guo X; Lv X
    BMC Cancer; 2017 Feb; 17(1):134. PubMed ID: 28202000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china.
    Chen Y; Liu MZ; Liang SB; Zong JF; Mao YP; Tang LL; Guo Y; Lin AH; Zeng XF; Ma J
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1356-64. PubMed ID: 18472356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis.
    Ribassin-Majed L; Marguet S; Lee AWM; Ng WT; Ma J; Chan ATC; Huang PY; Zhu G; Chua DTT; Chen Y; Mai HQ; Kwong DLW; Cheah SL; Moon J; Tung Y; Chi KH; Fountzilas G; Bourhis J; Pignon JP; Blanchard P
    J Clin Oncol; 2017 Feb; 35(5):498-505. PubMed ID: 27918720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A network meta-analysis for efficacies and toxicities of different therapeutic regimens in the treatment of advanced nasopharyngeal carcinoma.
    Li T; Yang F; Ma K; Lv L
    Eur Arch Otorhinolaryngol; 2021 Sep; 278(9):3333-3344. PubMed ID: 33517538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial.
    Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
    Eur J Cancer; 2017 Apr; 75():150-158. PubMed ID: 28235726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Which treatment is better than concurrent chemoradiotherapy about survival for stage III or IV locally advanced nasopharyngeal carcinoma? An updated Bayesian network meta-analysis of randomized controlled trials.
    Fang L; Shi L; Wang W; Hu T; Rao X
    Eur Arch Otorhinolaryngol; 2021 Oct; 278(10):3633-3642. PubMed ID: 33598731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
    Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
    Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Li WF; Chen L; Sun Y; Ma J
    Chin J Cancer; 2016 Nov; 35(1):94. PubMed ID: 27846913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A network meta-analysis of the sequencing and types of systemic therapies with definitive radiotherapy in locally advanced squamous cell carcinoma of the head and neck (LASCCHN)☆.
    Jerzak KJ; Delos Santos K; Saluja R; Lien K; Lee J; Chan KKW
    Oral Oncol; 2017 Aug; 71():1-10. PubMed ID: 28688674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy with or without adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: meta-analysis of 1,096 patients from 11 randomized controlled trials.
    Liang ZG; Zhu XD; Tan AH; Jiang YM; Qu S; Su F; Xu GZ
    Asian Pac J Cancer Prev; 2013; 14(1):515-21. PubMed ID: 23534786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
    Sun Y; Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J
    Lancet Oncol; 2016 Nov; 17(11):1509-1520. PubMed ID: 27686945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group.
    Chua DT; Sham JS; Choy D; Lorvidhaya V; Sumitsawan Y; Thongprasert S; Vootiprux V; Cheirsilpa A; Azhar T; Reksodiputro AH
    Cancer; 1998 Dec; 83(11):2270-83. PubMed ID: 9840526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
    Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
    Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone on locally advanced nasopharyngeal carcinoma.
    Liu H; Ding XR; Song YQ; Jiang C; Zhong XM; Hui HX
    J Biol Regul Homeost Agents; 2020; 34(6):2115-2119. PubMed ID: 33191713
    [No Abstract]   [Full Text] [Related]  

  • 37. Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis.
    Pasquali S; Yim G; Vohra RS; Mocellin S; Nyanhongo D; Marriott P; Geh JI; Griffiths EA
    Ann Surg; 2017 Mar; 265(3):481-491. PubMed ID: 27429017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Feasibility and efficacy of chemoradiotherapy for elderly patients with locoregionally advanced nasopharyngeal carcinoma: results from a matched cohort analysis.
    Liu H; Chen QY; Guo L; Tang LQ; Mo HY; Zhong ZL; Huang PY; Luo DH; Sun R; Guo X; Cao KJ; Hong MH; Mai HQ
    Radiat Oncol; 2013 Mar; 8():70. PubMed ID: 23521779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
    Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
    Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Chemoradiotherapy Regimens and Survival Among Patients With Nasopharyngeal Carcinoma: A Systematic Review and Meta-analysis.
    Zhang B; Li MM; Chen WH; Zhao JF; Chen WQ; Dong YH; Gong X; Chen QY; Zhang L; Mo XK; Luo XN; Tian J; Zhang SX
    JAMA Netw Open; 2019 Oct; 2(10):e1913619. PubMed ID: 31626318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.